Aroa Biosurgery (ARX) Stock Price, News & Analysis

Company Overview

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and OviTex and OviTex PRS, a reinforced bioscaffolds for use in hernia repair and abdominal wall reconstruction, as well as breast reconstruction. The company also offers Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: A$193.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: ASX:ARX
• CIK: N/A
• Web: www.arcexploration.com.au
• Phone: 61 8 6117 0452
• Fax: N/A
• Employees: 147,000
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$10.63 million
• Net Margins: -15.39%
• Pretax Margin: N/A
• Return on Equity: -11.09%
• Return on Assets: -5.86%

Debt

• Debt-to-Equity Ratio: 7.83
• Current Ratio: 7.26
• Quick Ratio: 8.39

Sales & Book Value

• Annual Sales: A$69.07 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 2.37
• Book Value: A$0.25 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 344,900,000
• Free Float: N/A
• Market Cap: A$193.14 million
• Optionable: Not Optionable
• Beta: 0.69